16800 West Twelve Mile Road
Suite 201, Southfield, MI 48076

Spinning Globe

DNA Design


Johnson & Johnson Licenses Core Drug Discovery Technology Platform from Housey Pharma

Johnson & Johnson, the world’s second largest pharmaceutical company by R&D expenditures, has entered into a license agreement with Housey Pharma to license its core enabling technologies for new drug discovery directed toward difficult and undruggable targets in the human genome.  This highly promising area of research in medicine may lead to a host of novel treatments for diseases such as drug-resistant cancers, diabetes, cardiovascular disease, CNS disorders such as dementia, and many other disease states for which current technologies were lacking.

“We are pleased to share this core technology with our scientific colleagues at Johnson & Johnson’s Janssen Pharmaceutical Research Institute.  We are excited by the use of these technologies throughout the industry in the in search for new medicines that will benefit us all” said Dr. Gerard Housey, M.D., Ph.D., President and CEO of Housey Pharma.

Therapeutic Discovery Tax Grants Awarded

HPRL Awarded Qualifying Therapeutic Discovery Tax Grants for two of its on-going research programs; “Novel Inhibitors for the Treatment of Highly Drug-Resistant Chronic Myelogenous Leukemia” and “Discovery and Development of Anti-Diabetic Drugs.”

2009 Lasker Award

Dr. Charles Sawyers shares the 2009 Lasker Award for his work elucidating the mechanism of drug-resistance in Chronic Myelogenous Leukemia (CML).